Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

美国疾病控制与预防中心（CDC）新冠数据追踪网站中，按疫苗接种状态划分的新冠病毒（COVID-19）病例及死亡发生率数据集。点击‘更多’查看重要数据集描述及脚注。

数据集与数据可视化详情：本数据于2022年10月21日发布，2022年11月18日归档，并于2023年2月22日修订。数据涵盖2022年9月24日之前（含当日）标本采集结果呈阳性者的病例，以及2022年9月3日之前（含当日）标本采集结果呈阳性者的死亡案例。

疫苗接种状态：完成FDA授权或批准的新冠疫苗基础接种系列（primary series）且经核实的个体，若其呼吸道标本在完成接种≥14天后检测出SARS-CoV-2 RNA或抗原，则计入病例。未接种者指呼吸道标本检测出SARS-CoV-2 RNA或抗原，且未核实已接种新冠疫苗的个体。排除人群为部分接种者：已接种至少一剂FDA授权疫苗，但在检测出SARS-CoV-2 RNA或抗原的标本采集前≥14天仍未完成基础接种系列的个体。

追加或加强针（additional or booster dose）：完成基础接种系列且接种了追加或加强针的个体，若其呼吸道标本在2021年8月13日及之后接种追加或加强针≥14天后检测出SARS-CoV-2 RNA或抗原，则计入病例。

18岁及以上人群：数据图表起始于2021年9月24日所在周，即CDC首次推荐65岁以上成人、特定人群及高风险职业与机构环境中的个体接种新冠加强针的时间。

12-17岁人群：数据图表起始于2021年12月26日所在周，即首次推荐16-17岁青少年接种加强针两周后。

5-11岁人群：数据自2022年6月5日所在周起纳入，即首次推荐该年龄段儿童接种加强针两周后。

50岁及以上人群：第二加强针相关数据图表起始于2022年3月29日所在周，即该年龄段第二加强针推荐发布时间。

竖线代表美国新冠疫苗接种政策发生变更的日期（详情见上文）。报告按基础接种系列的疫苗类型而非追加或加强针的疫苗类型统计，加强针疫苗类型可能与基础接种系列不同。

** 由于缺乏病例及相关死亡个体的免疫状态数据，无法区分免疫功能低下者接种的追加针与加强针。这一因素需重点考量，因为疫苗在此群体中的效果可能较弱。

死亡：新冠相关死亡指确诊新冠且死亡的个体，由卫生部门工作人员通过生命记录、公共卫生调查或其他数据源审核确定。按疫苗接种状态划分的新冠死亡发生率，依据患者新冠检测日期而非死亡日期统计。死亡通常发生在新冠确诊后30天内。

参与辖区：目前，31个定期将病例监测数据与免疫信息系统数据关联的卫生部门被纳入发病率估算，包括：阿拉巴马州、亚利桑那州、阿肯色州、加利福尼亚州、科罗拉多州、康涅狄格州、哥伦比亚特区、佛罗里达州、佐治亚州、爱达荷州、印第安纳州、堪萨斯州、肯塔基州、路易斯安那州、马萨诸塞州、密歇根州、明尼苏达州、内布拉斯加州、新泽西州、新墨西哥州、纽约州、纽约市（纽约州）、北卡罗来纳州、费城（宾夕法尼亚州）、罗得岛州、南达科他州、田纳西州、得克萨斯州、犹他州、华盛顿州及西弗吉尼亚州；其中30个辖区还报告了接种与未接种人群的死亡数据。这些辖区覆盖美国总人口的72%，并包含卫生与公众服务部（Health and Human Services, HHS）的所有10个区域。病例数据